Theriva Biologics, Inc.
TOVX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000894158
No open-market purchases or sales by Theriva Biologics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $495.5K in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Theriva Biologics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 31 | 36 | +5 |
| Shares | 6.50M | 7.23M | +730.6K (+11.2%) |
| Value | $3.91M | $3.32M | −$591.0K (−15.1%) |
New holders (5)
Institutions that held Theriva Biologics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Gsa Capital Partners LLP | 275,240 | $126.0K | 0.01% |
| Susquehanna International Group, LLP | 21,997 | $10.0K | 0.00% |
| Mercer Global Advisors Inc | 20,000 | $9.00K | 0.00% |
| HRT Financial LP | 13,855 | $6.00K | 0.00% |
| Barclays PLC | 47 | $0 | 0.00% |
Sold out (0)
Institutions that held Theriva Biologics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
None.